Integrated Annual Report

Overview

The report presents UCB's 2019 performance as an integrated biopharmaceutical business, including revenue of EUR 4 913 million and 7 606 employees. It highlights a 35% GHG reduction target by 2030 alongside carbon neutrality for directly controlled operations. Environmental progress includes 94% electricity sourced from renewable sources and reductions in energy, water withdrawal and waste generation compared with 2015. The report also includes a GRI Core disclosure index and an independent limited assurance report covering selected ESG data.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2019
Period: 1 January 2019 – 31 December 2019
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level
SBTi status

Materiality

Assessment
Basis

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services